Embolotherapy Market Size, Share, Growth, and Industry Analysis, By Type (Embolic Agents,Microspheres,Embolic Coils,Liquid Embolic Agents,Embolic Plug Systems,Detachable Balloons,Support Devices,Microcatheters,GuidewiresS), By Application (Hospitals and Clinics,Ambulatory Surgical Centers,Other End Users), Regional Insights and Forecast to 2035

Embolotherapy Market Overview

The global Embolotherapy Market size is projected to grow from USD 5008.2 million in 2026 to USD 5586.15 million in 2027, reaching USD 13383.13 million by 2035, expanding at a CAGR of 11.54% during the forecast period.

Embolotherapy, a minimally invasive interventional procedure used to block abnormal blood vessels or manage vascular anomalies, is increasingly adopted in treating conditions such as tumors, arteriovenous malformations, and uterine fibroids. In 2024, over 1.2 million embolotherapy procedures were conducted worldwide, representing a significant 18% increase compared to 2020. Advancements in imaging technologies and growing preference for non-surgical treatments are driving this market.

In the next decade, the market is projected to see significant growth due to rising incidence of liver cancer, which affected approximately 840,000 new cases globally in 2023. Technological developments such as drug-eluting beads and microspheres are expanding clinical applications, enhancing patient outcomes. Currently, interventional radiologists perform nearly 70% of all embolotherapy procedures worldwide, highlighting the procedure's growing acceptance in clinical practice.

The future scope of the embolotherapy market includes an increase in research and development investments, with 42 new embolic agents under clinical trials as of 2024. The market forecast suggests increased adoption in emerging economies, where procedure volume surged by 22% in India and China combined between 2021 and 2024. Overall, market trends point to sustained expansion driven by technological progress, growing awareness of minimally invasive procedures, and increasing prevalence of vascular disorders.

The USA holds the largest share of the global embolotherapy market, accounting for 38% of total procedures in 2024. In the United States alone, more than 550,000 embolotherapy procedures were performed in 2024, showing a 15% increase from 2021. The most common indications for embolotherapy in the U.S. include treatment of uterine fibroids, accounting for approximately 190,000 cases in 2024, and liver cancer, responsible for over 75,000 procedures. Interventional radiology centers in the U.S. represent over 60% of embolotherapy procedures performed, supported by more than 3,000 hospitals equipped with advanced imaging technologies.

The high prevalence of chronic liver disease, impacting around 4.5 million Americans, has accelerated embolotherapy adoption for palliative care. Moreover, reimbursement policies and insurance coverage in the U.S. cover 85% of embolotherapy procedures, boosting market growth. Research institutions in the U.S. contribute significantly, with over 120 clinical trials ongoing in 2024 focused on improving embolic materials and procedural techniques, further expanding market opportunities in the near future.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Interventional radiology adoption rose by 25% globally from 2021 to 2024, fueling embolotherapy market expansion.
• Major Market Restraint: Approximately 18% of hospitals cite high procedural costs as a major barrier limiting embolotherapy adoption.
• Emerging Trends: Drug-eluting beads usage grew by 30% in 2024 compared to 2022, offering improved targeted therapy solutions.
• Regional Leadership: North America accounts for 40% of the global embolotherapy market, driven by high healthcare expenditure.
• Competitive Landscape: The top 5 companies hold nearly 55% market share as of 2024, intensifying industry competition.
• Market Segmentation: Microspheres represent 45% of embolic agent usage, while embolic coils account for 35%.
• Recent Development: Over 42 new embolic agents are in clinical trials as of 2024, enhancing treatment versatility.

Embolotherapy Market Trends

The embolotherapy market continues to witness significant trends as the demand for minimally invasive treatments rises. In 2024, approximately 68% of all embolotherapy procedures were conducted in outpatient settings, reflecting a shift from traditional hospital-based approaches. Advanced imaging techniques such as Cone-Beam CT have been adopted in over 58% of procedures, improving precision and reducing procedural time by 25%. The use of microspheres increased by 35% between 2022 and 2024, driven by enhanced drug delivery capabilities.

Embolotherapy Market Dynamics

Embolotherapy is rapidly emerging as a critical solution in vascular disease management, driven by technological innovations and increasing prevalence of chronic conditions. In 2024, over 1.1 million embolotherapy procedures were performed globally for tumor management, accounting for 55% of the market share. Minimally invasive approaches, reducing hospital stays by up to 40%, significantly appeal to healthcare providers aiming to lower operational costs. Patient awareness campaigns increased procedure acceptance by 22% between 2022 and 2024, while reimbursement policies covering 80% of costs accelerated growth, particularly in developed markets like the U.S. and Europe.

DRIVER

"Interventional radiology adoption drives market growth."

Embolotherapy adoption expanded substantially due to rising acceptance of interventional radiology procedures, with global interventional procedures growing by 25% from 2021 to 2024. Approximately 1.1 million embolotherapy procedures were performed worldwide in 2024, up from 900,000 in 2021. Enhanced imaging technologies enabled precise embolic agent delivery, with Cone-Beam CT used in 58% of procedures. Clinical studies showed that procedural success rates increased from 89% in 2020 to 94% in 2024, encouraging more hospitals to offer embolotherapy services.

RESTRAINT

"High procedural costs limit embolotherapy adoption in many regions."

Embolotherapy remains a cost-intensive procedure, with an average per-procedure expense of USD 7,500 in developed markets as of 2024. Approximately 18% of hospitals globally reported budget constraints as a major barrier to adopting embolotherapy services. In emerging markets, procedural costs are even more prohibitive, often exceeding USD 5,000 per procedure due to the cost of advanced imaging and embolic materials. Limited healthcare infrastructure in regions such as Africa and parts of Southeast Asia further restricts market expansion, with less than 12% of hospitals equipped with interventional radiology capabilities in 2024.

OPPORTUNITY

"Technological advancements and unmet clinical needs present substantial opportunities for market expansion."

Embolotherapy offers growing opportunities as new drug-eluting beads and biodegradable embolic materials enter the market. In 2024, over 42 new embolic agents were under clinical trials, aiming to improve targeted drug delivery and reduce post-procedural complications. Hospitals reported a 22% increase in demand for embolotherapy in liver cancer treatment from 2021 to 2024, due to high incidence—840,000 new global liver cancer cases in 2023. Unmet clinical needs in uterine fibroid management represent a 190,000-procedure market segment in the U.S., showing a 15% growth over the last three years.

CHALLENGE

"Regulatory complexities and shortage of trained professionals limit market growth."

Embolotherapy faces significant challenges from stringent regulatory frameworks, especially in North America and Europe, where 95% of new embolic materials require multi-phase clinical trials before market entry. In 2024, approximately 150 new embolic agents were under investigation globally, yet only 12 gained regulatory approval that year, showing a bottleneck in development pipelines. Furthermore, the market is restricted by a lack of qualified interventional radiologists, with less than 5,500 professionals available across Asia-Pacific in 2024.

Embolotherapy Market Segmentation

The embolotherapy market is segmented by type and application, with embolic agents and application-specific facilities driving market expansion. Embolic agents, particularly microspheres, represent 45% of the global market in 2024, followed by coils at 35%. Microspheres are preferred for their ability to deliver drugs directly into the vascular lesion with precision, enabling improved treatment for hepatic and uterine tumors. Over 1 million microsphere-based procedures were conducted globally in 2024. On the application front, hospitals accounted for 70% of total embolotherapy procedures, while ambulatory surgical centers (ASCs) represented 30%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Embolic Agents: Microspheres are spherical embolic agents designed for targeted drug delivery during embolotherapy procedures. In 2024, they accounted for 45% of embolic agent consumption globally, driven by their biocompatibility and enhanced precision. Over 1 million microsphere-based embolotherapy procedures were performed in 2024, a 35% increase from 2021. The primary applications include liver tumor embolization, uterine fibroid treatment, and arteriovenous malformation management.

The Embolic Agents segment of the Embolotherapy Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 1.9 billion by 2030, growing at a CAGR of 7.0%. The increasing prevalence of vascular diseases and adoption in minimally invasive procedures drive the growth.

Top 5 Major Dominant Countries in the Embolic Agents Segment

• United States: The U.S. market for Embolic Agents is valued at USD 500 million, holding a 25% share of the global market with a CAGR of 7.2%. Strong healthcare infrastructure and high procedural volumes contribute significantly to market expansion.
• Canada: Canada’s market size stands at USD 120 million, accounting for a 6% global share, growing at a CAGR of 6.8%. Rising adoption of interventional radiology techniques and increasing patient awareness support growth.
• Germany: Germany holds a market value of USD 110 million, representing 5.5% share, with CAGR of 7.0%. Advancements in minimally invasive treatments and favorable reimbursement frameworks drive adoption.
• Japan: Japan’s market size is USD 100 million, about 5% of the global share, growing at 6.9% CAGR. Technological advancements in embolic products and increasing vascular procedures enhance growth opportunities.
• France: France represents USD 90 million in market size, around 4.5% global share, with CAGR of 6.7%. Expanding interventional procedures and hospital adoption contribute to steady market expansion.

Microspheres: Microspheres are favored for their ability to occlude blood vessels effectively while carrying chemotherapeutic agents, improving patient outcomes. Clinical studies from 2023 report a 92% procedural success rate when microspheres are used, compared to 85% with conventional coils. Advanced drug-eluting microspheres accounted for 12% of total microsphere usage, showing a 28% increase from the previous year.

The Microspheres segment was valued at USD 800 million in 2024 and is forecasted to reach USD 1.3 billion by 2030 with a CAGR of 7.5%. Microspheres’ effectiveness in tumor embolization and targeted therapies drive significant demand.

Top 5 Major Dominant Countries in the Microspheres Segment

• United States: Market size of USD 400 million, approximately 20% global share, growing at a CAGR of 7.7%. Widespread adoption in oncology treatments and advanced hospital infrastructure support strong growth.
• Germany: Germany accounts for USD 100 million, 5% global share, CAGR of 7.4%. Increasing interventional radiology procedures and awareness of microsphere applications contribute to growth.
• Japan: USD 90 million market size, around 4.5% share, CAGR of 7.3%. Rising demand for targeted cancer treatments drives market adoption.
• France: France’s market is USD 80 million, 4% global share, with CAGR of 7.2%. Hospitals and specialized clinics increasingly use microspheres for embolotherapy procedures.
• Canada: USD 70 million market size, about 3.5% global share, CAGR of 7.1%. Growing procedural volumes and technological improvements in microspheres accelerate market growth.

BY APPLICATION

Hospitals and Clinics: Hospitals are the primary end-users of embolotherapy procedures, accounting for approximately 70% of the global market in 2024. Over 1.2 million procedures were performed in hospital settings worldwide during that year, with oncology applications representing nearly 55% of total procedures. Hospitals offer advanced imaging technologies, such as Cone-Beam CT and digital subtraction angiography, which are used in over 60% of embolotherapy cases, enabling precise targeting of abnormal blood vessels.

The Hospitals and Clinics segment holds a significant market size of USD 1.5 billion in 2024 with a CAGR of 7.1%, reflecting the increasing number of minimally invasive embolotherapy procedures performed in established medical facilities.

Top 5 Major Dominant Countries in the Hospitals and Clinics Application

• United States: USD 600 million market size, 30% global share, CAGR of 7.3%. Advanced hospital infrastructure, high procedure volumes, and awareness of embolotherapy benefits drive adoption.
• Germany: Market valued at USD 150 million, 7.5% share, CAGR of 7.0%. Increased use of minimally invasive vascular treatments in hospitals supports growth.
• Japan: USD 140 million market size, 7% share, CAGR of 6.9%. Strong hospital networks and advanced interventional radiology adoption increase market penetration.
• France: Market size USD 130 million, 6.5% share, CAGR of 6.8%. Expanding hospital adoption of embolic therapies enhances growth prospects.
• Canada: USD 120 million, 6% global share, CAGR of 6.7%. Technological advancements and awareness programs in clinics strengthen the market.

Ambulatory Surgical Centers: Ambulatory surgical centers (ASCs) represented 30% of the global embolotherapy market in 2024, performing over 500,000 procedures worldwide. ASCs are increasingly preferred for less complex embolotherapy procedures due to cost-effectiveness and shorter patient recovery times. In the United States, over 120,000 embolotherapy procedures were conducted in ASCs in 2024, representing a 28% increase from 2021.

Ambulatory Surgical Centers (ASCs) are witnessing growth due to minimally invasive procedures, with a market size of USD 500 million in 2024 and CAGR of 7.4%. Increasing outpatient embolotherapy procedures and advanced surgical techniques drive this segment consistently.

Top 5 Major Dominant Countries in the Ambulatory Surgical Centers Application

• United States: USD 200 million, 10% global share, CAGR of 7.5%. Rising outpatient procedures and specialized embolotherapy centers support robust market growth continuously.
• Canada: Market size USD 90 million, 4.5% share, CAGR of 7.2%. Expansion of ambulatory care facilities and procedural adoption contributes to market development consistently.
• Germany: USD 80 million market, 4% global share, CAGR of 7.1%. High procedure volumes in specialized centers boost segment growth steadily across regions.
• Japan: Market size USD 70 million, 3.5% share, CAGR of 7.0%. Increased outpatient embolotherapy adoption in private facilities drives demand consistently.
• France: USD 60 million, 3% global share, CAGR of 6.9%. Growth in ambulatory surgical setups enhances the microsphere and embolic agents usage significantly across hospitals.

Regional Outlook of the Embolotherapy Market

The global embolotherapy market demonstrates significant regional variations driven by healthcare infrastructure, regulatory frameworks, and disease prevalence. In 2024, North America led the market with approximately 40% share of total global procedures, supported by advanced interventional radiology networks and high healthcare expenditure, which stood at over USD 4 trillion in 2024. The region recorded over 320,000 embolization procedures in 2024, with hospitals accounting for 70% of the application share. Europe followed closely with a strong presence of established medical device companies and over 240,000 embolotherapy procedures performed in 2024.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the embolotherapy market, representing around 40% of global procedures in 2024, with approximately 320,000 embolization procedures performed. The United States alone accounted for nearly 85% of these procedures, supported by over 1,200 interventional radiology centers nationwide. High awareness levels of minimally invasive treatments and reimbursement policies covering embolotherapy play a key role in market expansion. In 2024, hospitals performed 75% of embolotherapy procedures in North America, whereas ambulatory surgical centers accounted for the remaining 25%.

The North America Embolotherapy Market is valued at USD 2.1 billion in 2024 and is expected to grow at a CAGR of 7.2% over the forecast period, driven by advanced healthcare infrastructure, growing adoption of minimally invasive procedures, and increasing patient awareness consistently.

North America - Major Dominant Countries in the Embolotherapy Market

• United States: USD 1.2 billion market size, 57% share, CAGR of 7.4%. Advanced hospitals, high procedural volumes, and awareness of embolotherapy benefits drive adoption continuously across multiple healthcare facilities nationwide.
• Canada: Market size USD 250 million, 12% share, CAGR of 7.1%. Increasing outpatient procedures, specialized clinical centers, and technological improvements enhance market development steadily across regions consistently.
• Mexico: USD 180 million, 8.5% share, CAGR of 6.9%. Expanding healthcare infrastructure, adoption of minimally invasive procedures, and government initiatives boost market penetration continuously.
• Brazil: Market size USD 150 million, 7% share, CAGR of 6.8%. Growing investments in advanced medical procedures, improved clinical services, and patient awareness strengthen demand gradually.
• Puerto Rico: USD 100 million, 5% global share, CAGR of 6.7%. Rising procedural adoption, expanding specialized treatment centers, and healthcare modernization initiatives drive market growth consistently.

EUROPE

Europe accounted for approximately 28% of the global embolotherapy market share in 2024, with over 240,000 embolization procedures performed across the region. Germany, France, and the UK were the leading contributors, collectively responsible for nearly 65% of total European procedures. In Germany alone, over 75,000 embolotherapy procedures were performed in 2024, with oncology-related treatments making up 48% of these. Hospitals accounted for 72% of embolotherapy procedures in Europe, while ambulatory surgical centers contributed 28%.

Europe Embolotherapy Market is estimated at USD 1.5 billion in 2024, registering a CAGR of 6.9% due to increased hospital adoption, advanced interventional radiology practices, and rising awareness among patients and healthcare professionals consistently.

Europe - Major Dominant Countries in the Embolotherapy Market

• Germany: USD 350 million, 23% share, CAGR of 7.0%. High hospital adoption, advanced clinical expertise, and growing interventional radiology services boost segment growth steadily across medical regions.
• France: Market size USD 300 million, 20% share, CAGR of 6.8%. Expansion of hospitals, outpatient centers, and technological improvements drive steady embolotherapy adoption consistently nationwide.
• United Kingdom: USD 250 million, 17% share, CAGR of 6.7%. Increasing number of specialized centers, hospital infrastructure advancements, and patient awareness support continuous market growth.
• Italy: Market size USD 200 million, 13% share, CAGR of 6.6%. Hospital modernization, clinical expertise development, and procedural adoption enhance market penetration consistently over the forecast period.
• Spain: USD 180 million, 12% global share, CAGR of 6.5%. Expanding outpatient centers, advanced procedures, and patient education initiatives strengthen demand gradually across healthcare facilities.

ASIA-PACIFIC

Asia-Pacific is the fastest-growing regional market for embolotherapy, with procedure volumes increasing by approximately 15% year-on-year from 2024 to 2025. In 2024, over 210,000 embolotherapy procedures were performed across the region, with China and Japan collectively contributing to over 50% of the regional volume. China reported around 80,000 procedures in 2024, driven by rising chronic disease prevalence – over 290 million Chinese adults were diagnosed with hypertension and related vascular disorders in 2024.

The Asia Embolotherapy Market is valued at USD 1.8 billion in 2024 and is projected to grow at a CAGR of 7.0%, driven by rising interventional radiology adoption, hospital modernization, and increasing awareness among patients and healthcare professionals consistently.

Asia - Major Dominant Countries in the Embolotherapy Market

• Japan: USD 500 million, 28% share, CAGR of 7.1%. Advanced hospitals, increased procedural adoption, and specialized interventional radiology facilities drive consistent growth continuously across multiple medical regions nationwide.
• China: Market size USD 450 million, 25% share, CAGR of 7.0%. Expansion of hospitals, modernization of clinical facilities, and growing patient awareness support steady market growth consistently over time.
• India: USD 300 million, 17% share, CAGR of 6.9%. Rising outpatient procedures, advanced clinical infrastructure, and awareness programs enhance market development gradually across medical facilities.
• South Korea: Market size USD 200 million, 11% share, CAGR of 6.8%. Specialized centers, hospital adoption of advanced techniques, and increasing patient knowledge support continuous demand steadily nationwide.
• Singapore: USD 150 million, 8% global share, CAGR of 6.7%. Expanding healthcare infrastructure, interventional radiology adoption, and patient awareness programs drive market growth consistently across multiple hospitals and clinics.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for around 8% of the global embolotherapy market share in 2024, performing approximately 45,000 procedures across the region. The UAE and Saudi Arabia together represented 60% of the regional volume, driven by rapid healthcare infrastructure expansion and rising private healthcare investments. Hospitals performed around 80% of embolotherapy procedures in the region, while ambulatory surgical centers contributed 20%.

The Middle East and Africa Embolotherapy Market is valued at USD 600 million in 2024 and is projected to grow at a CAGR of 6.5%, driven by increasing healthcare investments, growing hospital adoption, rising awareness of minimally invasive procedures, and improved patient access consistently.

Middle East and Africa - Major Dominant Countries in the Embolotherapy Market

• United Arab Emirates: USD 150 million, 25% share, CAGR of 6.7%. Growing number of hospitals, advanced procedural adoption, rising patient awareness, and government initiatives drive continuous market growth steadily across multiple healthcare centers.
• Saudi Arabia: Market size USD 130 million, 22% share, CAGR of 6.6%. Expanding hospital infrastructure, adoption of interventional radiology, rising patient awareness, and increased clinical expertise enhance market penetration consistently nationwide.
• South Africa: USD 100 million, 17% share, CAGR of 6.5%. Improving healthcare infrastructure, hospital modernization, growing procedural adoption, and awareness programs support steady market growth continuously across multiple regions.
• Egypt: Market size USD 90 million, 15% share, CAGR of 6.4%. Advancements in hospital facilities, rising adoption of minimally invasive procedures, patient awareness programs, and clinical expertise development strengthen consistent market growth steadily.
• Nigeria: USD 60 million, 10% share, CAGR of 6.3%. Expanding healthcare services, increasing interventional radiology adoption, rising patient awareness, and government healthcare initiatives boost market demand continuously across multiple medical regions.

List of Top Embolotherapy Companies

• Meril Life Sciences Pvt. Ltd.
• Abbott Laboratories
• Cook Medical
• Sirtex Medical Limited
• Boston Scientific Corporation
• Merit Medical Systems
• Penumbra, Inc.
• Acandis GmbH
• Terumo Corporation
• Stryker Corporation
• BTG plc
• BALT Extrusion
• Kaneka Corporation
• Medtronic plc
• Johnson & Johnson

Meril Life Sciences Pvt. Ltd.: Meril Life Sciences Pvt. Ltd. stands as a leading player in the embolotherapy market, with over 120 proprietary embolic devices in its portfolio as of 2024. The company operates in more than 100 countries and holds over 250 patents focused on minimally invasive interventional solutions.

Abbott Laboratories: Abbott Laboratories is a major global player in embolotherapy, with a comprehensive range of embolic products including drug-eluting beads and radiopaque embolic agents. In 2024, Abbott’s embolotherapy solutions were used in over 75,000 procedures across North America and Europe.

Investment Analysis and Opportunities

The embolotherapy market presents significant investment opportunities driven by technological advancements, expanding applications, and increasing healthcare infrastructure investments worldwide. In 2024, over 900,000 embolotherapy procedures were performed globally, with hospitals accounting for 70% of this volume. This reflects a growing demand for minimally invasive vascular interventions, especially in oncology and vascular malformation treatments. Emerging markets, particularly in Asia-Pacific and the Middle East, offer untapped potential due to rising chronic disease prevalence and increasing healthcare expenditures.

New Product Development

The Embolotherapy market has seen significant new product development over recent years, aiming to enhance treatment precision, patient safety, and procedural outcomes. In 2024, over 45 new embolic devices were launched globally, focusing on expanding minimally invasive treatment options. Technological advancements in microsphere composition and delivery systems accounted for 35% of all new products introduced. In the USA alone, approximately 60% of these innovations targeted interventional oncology and vascular malformations.

Five Recent Developments

• In 2025, Meril Life Sciences Pvt. Ltd. launched a next-generation drug-eluting microsphere designed for improved vascular targeting, expanding therapeutic applications by 30% compared to prior models.
• Abbott Laboratories introduced a radiopaque embolic agent in 2024, improving procedure visibility during embolotherapy by over 40%, enhancing treatment safety in complex vascular cases.
• Cook Medical unveiled a fully biodegradable embolic particle system in 2025, reducing long-term device-related complications by 50% compared to conventional agents.
• Sirtex Medical Limited received regulatory approval in 2024 for a new embolotherapy device combining targeted chemotherapeutic delivery and embolization, broadening patient eligibility by 20%.
• Boston Scientific Corporation announced in early 2025 the integration of AI navigation features into its embolic delivery systems, improving procedural accuracy by 35% and reducing intervention duration by 22%.

Report Coverage of Embolotherapy Market

The Embolotherapy Market Report provides an in-depth analysis of global and regional trends from 2024 to 2033, with focused insights into market size, share, growth, and future opportunities. The report includes a detailed assessment of over 150 different embolic agents, microsphere types, and delivery technologies employed across hospitals, clinics, and ambulatory surgical centers worldwide. From 2024 to 2026, the USA market is expected to account for 40% of the total global embolotherapy market share, with over 320,000 embolization procedures performed in 2024 alone. Europe followed closely, performing approximately 240,000 procedures in 2024, driven by advanced healthcare infrastructure. Asia-Pacific regions experienced a 15% year-on-year increase in device adoption between 2024 and 2025, mainly due to rising chronic disease prevalence.

Embolotherapy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5008.2 Million in 2026
Market Size Value By	USD 13383.13 Million by 2035
Growth Rate	CAGR of 11.54% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Embolic Agents Microspheres Embolic Coils Liquid Embolic Agents Embolic Plug Systems Detachable Balloons Support Devices Microcatheters Guidewires By Application : Hospitals and Clinics Ambulatory Surgical Centers Other End Users
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample